Skip to content
value.today

NextRNA Therapeutics, Inc.

Formerly SeoRx Therapeutics, Inc.

Total raised
$23 M
1 round on record
Latest round
$23 M
Jan 2022
First round on record
Jan 2022
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of NextRNA Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2022$23 MNo. 1$10 to $50 million

NextRNA Therapeutics, Inc.: Raise no. 1, Jan 2022

Investors in this round

34 investors had bought by the notice of Jan 27, 2022: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $50 M offered; $27 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julia A. Novina · Executive Officer
  • Marc A. Cohen · Executive Officer, Director
  • Alain A. Cohen · Director
  • Andrea A. Armstrong · Director
  • Arthur A. Becker · Director
  • Barry A. Polisky · Director
  • Carl A. Novina · Director
  • Christine A. Henderson · Director
  • Dominique A. Verhelle · Director
  • Drew A. Dennison · Director
  • Elena A. Prokupets · Director
  • Fred A. Mermelstein · Director
  • Kenneth A. Anderson · Director
  • Malcolm A. Salter · Director
  • Susan A. Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Julia A. Novina, Chief Legal Officer. Newest notice filed Jan 27, 2022. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NextRNA Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2022).

    SEC Form D · Jan 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of NextRNA Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NextRNA Therapeutics, Inc.
NameRoleNamed in
Julia A. NovinaExecutive officerJan 2022
Marc A. CohenExecutive officerJan 2022
Alain A. CohenDirectorJan 2022
Andrea A. ArmstrongDirectorJan 2022
Arthur A. BeckerDirectorJan 2022
Barry A. PoliskyDirectorJan 2022
Carl A. NovinaDirectorJan 2022
Christine A. HendersonDirectorJan 2022
Dominique A. VerhelleDirectorJan 2022
Drew A. DennisonDirectorJan 2022
Elena A. ProkupetsDirectorJan 2022
Fred A. MermelsteinDirectorJan 2022
Kenneth A. AndersonDirectorJan 2022
Malcolm A. SalterDirectorJan 2022
Marc A. CohenDirectorJan 2022
Susan A. LangerDirectorJan 2022